technology
soloMERs® are Elasmogen’s proprietary biologics technology delivering multi-functional therapeutic products.
soloMERs® are single domain biologics with differentiated binding interactions driving new mechanisms of action. Their simple architecture enables rapid reformatting to generate effective multifunctional products.
Our pipeline focus is to deliver multi-functional products for the treatment of immune-mediated diseases including targeted soloMER drug conjugates and orally delivered bi-specific products.
Our pipeline also includes novel radiopharmaceutical therapies (RPT) that exploit the highly specific, high affinity and multi-functional advantages of our soloMERs® platform.
reformatting of soloMERs®
The simple, single-chain nature of soloMERs® enables rapid reformatting into different drug products, tailored for optimal therapeutic efficacy. The advantages of small size, such as greater tumour and tissue penetration, can be retained whilst increasing the functionality of the product by creating dimeric and trimeric soloMER® fusions. Furthermore, the PK of these constructs can be tailored through the inclusion of our proprietary albumin binding soloMER® , NDure®. The amenability to both N– and C– terminal molecular fusions without loss of function or favourable biophysical properties has led to the creation of a portfolio of empirically designed multivalent soloMER® modalities.
By applying our robust but rationally informed reformatting techniques, a range of multi-valent, biparatopic, multispecific soloMERs® with enhanced in vitro potency and in vivo efficacy have been created. The soloMER® Quad® is a family of multispecific or multi-paratopic human IgG1 Fc fused soloMERs® , exhibiting super-potent activity in disease models.
soloMER® drug engine
Elasmogen has multiple different libraries that deliver high affinity, highly selective soloMERs® against multiple target classes. These are the building blocks for our multi-functional product pipeline.
Elasmogen has a portfolio of drug libraries based on different isotype combinations and loop diversity creating a breadth of unique binding paratope topologies.
soloMER® libraries:
Our in depth knowledge of soloMERs® has enabled the rational design of multiple synthetic and immunised libraries that retain the desirable attributes of these domains whilst expanding on the diversity of the natural repertoire through clever isotype fusions.
Our libraries can deliver pM affinity domains against different target classes.
Our patent protected humanisation and de-immunisation methods have been incorporated into the library designs to reduce development time and fast-track our products into the clinic.
soloMER® Drug Conjugates (SDC)
- Autoimmune Products:
Synergistic, dual function efficacy has been achieved by conjugating a clinically validated small molecule to a potent anti-inflammatory soloMER® product. The cleavable linker ensures delivery directly at the site of inflammation.
- Oncology Products:
Elasmogen has developed a pipeline of soloMER® Radiopharmaceutical Therapies (sRPT) to specifically target and deliver radioisotopes into tumours resulting in cell death.
In partnership with Almac Discovery, a pipeline of soloMER drug conjugates has been developed to treat solid tumour cancers. These are now available for licensing.
oral delivery
Formulation of biologics for oral delivery is one of the most ambitious and disruptive development activities in the antibody therapeutics space. This approach will revolutionise patient care; most importantly improve drug safety and efficacy especially for site-specific disease targeting, e. g. IBD. Elasmogen is developing a pipeline of multi-functional anti-inflammatory soloMER® products for oral delivery to treat a wide range of diseases.
